| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Loss before income taxes | -7,545 | - | - | -11,083 |
| Income tax expense | 0 | - | - | 418 |
| Net loss | -7,545 | -24,296 | -24,123 | -11,501 |
| Unrealized gain (loss) on marketable securities, net of tax | 0 | 0 | -10 | 96 |
| Comprehensive loss | -7,545 | -24,296 | -24,133 | -11,405 |
| Net loss per share attributable to common stockholders basic (in dollars per share) | -1.51 | -4.87 | -0.19 | -0.09 |
| Net loss per share attributable to common stockholders diluted (in dollars per share) | -1.51 | -4.87 | -0.19 | -0.09 |
| Weighted-average number of shares of common stock used in net loss per share attributable to common stockholders basic (in shares) | 4,992,639 | 4,986,784 | 124,466,113 | 122,721,918 |
| Weighted-average number of shares of common stock used in net loss per share attributable to common stockholders diluted (in shares) | 4,992,639 | 4,986,784 | 124,466,113 | 122,721,918 |
Mersana Therapeutics, Inc. (MRSN)
Mersana Therapeutics, Inc. (MRSN)